Cleared Traditional

IMMUNOGLOBULIN ASSAYS-IGG, IGA, IGM (K823567) - FDA 510(k) Clearance

Class II Immunology device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K823567 · Syva Co. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1982
Decision
27d
Days
Class 2
Risk

K823567 is an FDA 510(k) clearance for the IMMUNOGLOBULIN ASSAYS-IGG, IGA, IGM. Classified as Iga, Antigen, Antiserum, Control (product code CZP), Class II - Special Controls.

Submitted by Syva Co. (Walker, US). The FDA issued a Cleared decision on December 30, 1982 after a review of 27 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5510 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Syva Co. devices

Submission Details

510(k) Number K823567 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 03, 1982
Decision Date December 30, 1982
Days to Decision 27 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
77d faster than avg
Panel avg: 104d · This submission: 27d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code CZP Iga, Antigen, Antiserum, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5510
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - CZP Iga, Antigen, Antiserum, Control

All 53
Devices cleared under the same product code (CZP) and FDA review panel - the closest regulatory comparables to K823567.
Yumizen C1200 Immunoglobulin A, Yumizen C1200 Immunoglobulin G, Yumizen C1200 Immunoglobulin M
K193525 · HORIBA ABX SAS · Jun 2020
N LATEX IGA
K024038 · Dade Behring, Inc. · Feb 2003
IGA
K983359 · Abbott Laboratories · Nov 1998
TDX IMMUNOGLOBULIN A DIAGNOSTIC KIT
K855046 · Abbott Laboratories · Aug 1986
IMMUNOGLOBULIN CONTROL
K823566 · Syva Co. · Dec 1982
A-GENT IMMUNOGLOBULINE TEST SYSTEM
K790479 · Abbott Laboratories · Apr 1979